Immune checkpoint inhibitors-related rheumatic diseases: what rheumatologist should know?

Basit Öğe Kaydı
dc.authoridŞenol Kobak / 0000-0001-8270-640Xen_US
dc.authorscopusidŞenol Kobak / 12782228700
dc.authorwosidŞenol Kobak / AAO-2482-2020
dc.contributor.authorGediz, Füsun
dc.contributor.authorKobak, Şenol
dc.date.accessioned2020-08-30T20:07:05Z
dc.date.available2020-08-30T20:07:05Z
dc.date.issued2019
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractImmune checkpoint inhibitors are revolutionized drugs for cancer immunotherapy in the last years. The mechanism of action of CPIs including the limitation of the activation of Tcells, and thus enhancing the self-immune response against tumour cells. Checkpointinhibitors(CPIs) may dysregulate the immune system, resulting in some toxicities. These toxicities or side effects are called Immune-related Adverse Events (IRAEs) that can potentially affect any organ and tissue. Rheumatic diseases due to checkpoint inhibitors are also reported in the literature. The spectrum of rheumatic manifestations are quite wide; the most common are arthralgia/arthritis, myalgia/myositis, polimyalgia rheumatica, lupus, rheumatoid arthritis, Sjogren's syndrome. At the same time, these drugs can also cause an exacerbation of known rheumatologic disease. Treatment approaches for developing rheumatic findings due to checkpoint inhibitors should be multidisciplinary. There should be a close relationship between oncologists who follow-up these patients and rheumatologists. The rheumatic manifestations should be defined and treated early. In general, the musculoskeletal side effects are transient and may regress after stopping CPIs. The most commonly used medications are corticosteroids. Immunosuppressive drugs (HQ, MTX, anti-TNF-alpha, anti-IL-6) should be preferred when treatment is unresponsive or as steroid-sparing agents. The aim of this review was to evaluate the checkpoint inhibitors-related rheumatologic findings and therapeutic strategies in light of recent literature data.en_US
dc.identifier.citationGediz, F., & Kobak, S. (2019). Immune Checkpoint Inhibitors-related Rheumatic Diseases: What Rheumatologist Should Know?. Current Rheumatology Reviews, 15(3), 201-208.en_US
dc.identifier.doi10.2174/1573397115666190119094736en_US
dc.identifier.endpage208en_US
dc.identifier.issn1573-3971en_US
dc.identifier.issn1875-6360en_US
dc.identifier.issue3en_US
dc.identifier.pmid30659547en_US
dc.identifier.scopus2-s2.0-85070704508en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage201en_US
dc.identifier.urihttps://doi.org/10.2174/1573397115666190119094736
dc.identifier.urihttps://hdl.handle.net/20.500.12713/691
dc.identifier.volume15en_US
dc.identifier.wosWOS:000478017300003en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorKobak, Şenolen_US
dc.language.isoenen_US
dc.publisherBentham Science Publ Ltden_US
dc.relation.ispartofCurrent Rheumatology Reviewsen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectImmune-Checkpoint Inhibitorsen_US
dc.subjectRheumatic Diseasesen_US
dc.subjectFeaturesen_US
dc.subjectTreatmenten_US
dc.subjectApproachesen_US
dc.subjectTherapeutic Strategiesen_US
dc.titleImmune checkpoint inhibitors-related rheumatic diseases: what rheumatologist should know?en_US
dc.typeReview Articleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
170.pdf
Boyut:
312.17 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu